title: Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.
abstract: Aberrant epigenetic regulation of gene expression contributes to tumor initiation and progression. Studies from a plethora of hematologic and solid tumors support the use of histone deacetylase inhibitors (HDACi) as potent anticancer agents. However, the mechanism of HDACi action with respect to the temporal order of induced cellular events is unclear. The present study investigates the anticancer effects of the HDACi trichostatin A in high-grade childhood brain tumor cells. Acute exposure to trichostatin A resulted in marked inhibition of cell proliferation, an increase in the proportion of G(2)-M cells, activation of H2A.X, and subsequent induction of apoptosis in the majority of cell lines. These phenotypic effects were associated with abrogation of telomerase activity and human telomerase reverse transcriptase downregulation in the majority of cell lines. In contrast, no cytotoxicity was observed in primary ependymal cells with respect to cilia function. Thus, inhibition of histone deacetylases leads to antiproliferative and proapoptotic effects in childhood brain tumor cells, likely to involve altered chromatin regulation at the human telomerase reverse transcriptase promoter.
authors.affiliation: Children's Brain Tumor Research Centre, Medical School, University of Nottingham, Nottingham, United Kingdom.
authors.forename: Ruman
authors.initials: R
authors.lastname: Rahman
authors.forename: Teresa
authors.initials: T
authors.lastname: Osteso-Ibanez
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hirst
authors.forename: Jane
authors.initials: J
authors.lastname: Levesley
authors.forename: John-Paul
authors.initials: JP
authors.lastname: Kilday
authors.forename: Siobhan
authors.initials: S
authors.lastname: Quinn
authors.forename: Andrew
authors.initials: A
authors.lastname: Peet
authors.forename: Chris
authors.initials: C
authors.lastname: O'Callaghan
authors.forename: Beth
authors.initials: B
authors.lastname: Coyle
authors.forename: Richard G
authors.initials: RG
authors.lastname: Grundy
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D048708:Cell Growth Processes / Q000187:drug effects; D002648:Child; D044127:Epigenesis, Genetic; D015870:Gene Expression / Q000187:drug effects; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D019098:Telomerase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; C012589:trichostatin A; D019098:Telomerase; D006655:Histone Deacetylases